Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome.
Kevin MooreKhurram JamilKatharina VerlegerLinlin LuoNehemiah KebedeMarieke HeisenShelby L CormanRoberta LeonardiRachel BakkerChristine MaïNisreen ShamseddineXingyue HuangAndrew S AllegrettiPublished in: Alimentary pharmacology & therapeutics (2020)
Terlipressin is the most commonly prescribed vasoconstrictor for patients with hepatorenal syndrome in the United Kingdom. Treatment with terlipressin in patients with less severe acute kidney injury (serum creatinine <2.25 mg/dL) was associated with higher treatment responses, and 90-day survival.